REG - GSK PLC - Director/PDMR Shareholding
15/10/2025 15:30
For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251015:nRSO4797Da&default-theme=true
RNS Number : 4797D GSK PLC 15 October 2025
GSK plc (the 'Company')
Transaction notification
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Emma Walmsley
b) Position/status Chief Executive Officer
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction Increase in notional interest in Ordinary Shares following the re-investment
of dividends paid to shareholders on 9 October 2025 on Ordinary Shares held in
the Company's Deferred Annual Bonus Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£16.4000 1,355
£16.4000 1,531
£16.4000 1,038
d) Aggregated information
Aggregated volume Price 3,924
£16.4000
e) Date of the transaction 2025-10-10
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Julie Brown
b) Position/status Chief Financial Officer
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction Increase in notional interest in Ordinary Shares following the re-investment
of dividends paid to shareholders on 9 October 2025 on Ordinary Shares held in
the Company's Deferred Annual Bonus Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£16.4000 680
£16.4000 584
d) Aggregated information
Aggregated volume Price 1,264
£16.4000
e) Date of the transaction 2025-10-10
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Diana Conrad
b) Position/status Chief People Officer
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction Increase in notional interest in Ordinary Shares following the re-investment
of dividends paid to shareholders on 9 October 2025 on Ordinary Shares held in
the Company's Deferred Annual Bonus Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£16.4000 152
£16.4000 386
£16.4000 246
d) Aggregated information
Aggregated volume Price 784
£16.4000
e) Date of the transaction 2025-10-10
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name James Ford
b) Position/status SVP and Group General Counsel, Legal and Compliance
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction Increase in notional interest in Ordinary Shares following the re-investment
of dividends paid to shareholders on 9 October 2025 on Ordinary Shares held in
the Company's Deferred Annual Bonus Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£16.4000 239
£16.4000 237
£16.4000 391
d) Aggregated information
Aggregated volume Price 867
£16.4000
e) Date of the transaction 2025-10-10
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Sally Jackson
b) Position/status SVP, Global Communications and CEO Office
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction Increase in notional interest in Ordinary Shares following the re-investment
of dividends paid to shareholders on 9 October 2025 on Ordinary Shares held in
the Company's Deferred Annual Bonus Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£16.4000 242
£16.4000 149
£16.4000 133
d) Aggregated information
Aggregated volume Price 524
£16.4000
e) Date of the transaction 2025-10-10
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Luke Miels
b) Position/status Chief Commercial Officer
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction Increase in notional interest in Ordinary Shares following the re-investment
of dividends paid to shareholders on 9 October 2025 on Ordinary Shares held in
the Company's Deferred Annual Bonus Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£16.4000 365
£16.4000 578
£16.4000 727
d) Aggregated information
Aggregated volume Price 1,670
£16.4000
e) Date of the transaction 2025-10-10
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Shobie Ramakrishnan
b) Position/status Chief Digital and Technology Officer
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument American Depositary Shares ('ADSs')
ISIN: US37733W2044
b) Nature of the transaction Increase in notional interest in ADSs following the re-investment of dividends
paid to shareholders on 9 October 2025 on ADSs held in the Company's Deferred
Annual Bonus Plan
c) Price(s) and volume(s) Price(s) Volume(s)
$43.4400 119
$43.4400 112
$43.4400 186
d) Aggregated information
Aggregated volume Price 417
$43.4400
e) Date of the transaction 2025-10-10
f) Place of the transaction New York Stock Exchange (XNYS)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name David Redfern
b) Position/status President, Corporate Development
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction Increase in notional interest in Ordinary Shares following the re-investment
of dividends paid to shareholders on 9 October 2025 on Ordinary Shares held in
the Company's Deferred Annual Bonus Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£16.4000 463
£16.4000 334
£16.4000 211
d) Aggregated information
Aggregated volume Price 1,008
£16.4000
e) Date of the transaction 2025-10-10
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Regis Simard
b) Position/status President, Global Supply Chain
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction Increase in notional interest in Ordinary Shares following the re-investment
of dividends paid to shareholders on 9 October 2025 on Ordinary Shares held in
the Company's Deferred Annual Bonus Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£16.4000 309
£16.4000 557
£16.4000 268
d) Aggregated information
Aggregated volume Price 1,134
£16.4000
e) Date of the transaction 2025-10-10
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Philip Thomson
b) Position/status President, Global Affairs
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction Increase in notional interest in Ordinary Shares following the re-investment
of dividends paid to shareholders on 9 October 2025 on Ordinary Shares held in
the Company's Deferred Annual Bonus Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£16.4000 188
£16.4000 311
£16.4000 175
d) Aggregated information
Aggregated volume Price 674
£16.4000
e) Date of the transaction 2025-10-10
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Deborah Waterhouse
b) Position/status CEO, ViiV Healthcare and President, Global Health, GSK
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction Increase in notional interest in Ordinary Shares following the re-investment
of dividends paid to shareholders on 9 October 2025 on Ordinary Shares held in
the Company's Deferred Annual Bonus Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£16.4000 427
£16.4000 482
£16.4000 290
d) Aggregated information
Aggregated volume Price 1,199
£16.4000
e) Date of the transaction 2025-10-10
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Tony Wood
b) Position/status Chief Scientific Officer
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction Increase in notional interest in Ordinary Shares following the re-investment
of dividends paid to shareholders on 9 October 2025 on Ordinary Shares held in
the Company's Deferred Annual Bonus Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£16.4000 594
£16.4000 202
£16.4000 271
d) Aggregated information
Aggregated volume Price 1,067
£16.4000
e) Date of the transaction 2025-10-10
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Emma Walmsley
b) Position/status Chief Executive Officer
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends paid
to shareholders on 9 October 2025 on Ordinary Shares held in the Company's
Performance Share Plan subject to a 2-year holding period
c) Price(s) and volume(s) Price(s) Volume(s)
£16.4000 4,590.351
£16.4000 4,196.389
d) Aggregated information N/A (single transaction)
Aggregated volume Price
8,786.741
£16.4000
e) Date of the transaction 2025-10-10
f) Place of the transaction London Stock Exchange (XLON)
d)
Aggregated information
Aggregated volume Price
N/A (single transaction)
8,786.741
£16.4000
e)
Date of the transaction
2025-10-10
f)
Place of the transaction
London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name David Redfern
b) Position/status President Corporate Development
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends paid
to shareholders on 9 October 2025 on Ordinary Shares held within an ISA
c) Price(s) and volume(s) Price(s) Volume(s)
£16.3499 20
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2025-10-10
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Victoria Whyte
b) Position/status Company Secretary
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends paid
to shareholders on 9 October 2025 on Ordinary Shares held within an ISA
c) Price(s) and volume(s) Price(s) Volume(s)
£16.3499 17
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2025-10-10
f) Place of the transaction London Stock Exchange (XLON)
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END DSHFFMSAIEISEES
Copyright 2019 Regulatory News Service, all rights reservedRecent news on GSK
See all newsREG - GSK PLC - Transaction in Own Shares
AnnouncementREG - GSK PLC - Positive data for low carbon version Ventolin MDI
AnnouncementREG - GSK PLC - Latozinemab data read out
AnnouncementREG - GSK PLC - Transaction in Own Shares
AnnouncementREG - GSK PLC - Positive CHMP Opinion for GSK on Shingrix PFS
Announcement